Cytokinetics Posts $1.50 Q4 Loss on $17.7 M Revenue, Myqorzo EU Debut Set
Cytokinetics reported a fourth-quarter net loss of $1.50 per share on $17.7 million in revenue, a 5% year-over-year increase that beat estimates by $13.7 million. Myqorzo (aficamten) received FDA approval for oHCM in December, with first EU launch planned in Q2 2026, intensifying competition with Bristol Myers Squibb’s Camzyos.
1. Q4 Financial Performance
Cytokinetics posted a net loss of $1.50 per share in Q4 2025, widening from a $1.26 loss year-over-year. Revenues rose 5% to $17.7 million, surpassing consensus by $13.7 million, driven by higher collaboration and milestone payments.
2. Cash Position and Runway
As of December 31, 2025, Cytokinetics held $1.22 billion in cash, equivalents and investments, bolstered by a $100 million draw on a loan facility. This strong liquidity underpins planned commercialization and multiple ongoing clinical programs through 2026.
3. Myqorzo Launch and Competitive Implications
Myqorzo (aficamten) obtained FDA approval for symptomatic obstructive hypertrophic cardiomyopathy in December, with the first European launch scheduled for Q2 2026. The rollout positions Cytokinetics to intensify competition against Bristol Myers Squibb’s Camzyos in the growing oHCM market.